Prevention of autoimmunity in experimental lupus erythematosus by soluble immune response suppressor.
Young NZB/W mice, treated with injections of soluble immune response suppressor (SIRS)(supernatant from mouse spleen cells exposed to concanavalin A), showed decreased immunoglobulin levels, less antibody to cell nuclei, less proteinuria, and less renal pathology as compared with NZB/W mice receiving a control preparation.  Thus, SIRS administration beginning at an early age appears to be an effective therapy of the autoimmune disease in NZB/W mice.
D000361:Agammaglobulinemia / Q000139:chemically induced; D000818:Animals; D000974:Antibodies, Antinuclear; D001323:Autoantibodies / Q000096:biosynthesis*; D004912:Erythrocytes / Q000276:immunology; D005921:Glomerulonephritis / Q000517:prevention & control; D007165:Immunosuppression Therapy; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000628:therapy*; D008222:Lymphokines / Q000009:adverse effects / Q000627:therapeutic use*; D051379:Mice; D008814:Mice, Inbred NZB / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D008222:Lymphokines